Please login to the form below

Not currently logged in
Email:
Password:

Jon Linscott to head Pan Advertising

He takes on the role of managing director at the healthcare advertising firm

Jon Linscott - Pan AdvertisingJon Linscott has been appointed managing director of Pan Advertising, a London-based part of Creston Health. 

He has been with Pan for nine years and spent the past two years as client services Director, focusing exclusively on key clients including GSK, Amgen and Astellas. 

Linscott said: “I am thrilled to have the opportunity to lead such a bright and talented team in what promises to be a new era for Pan Advertising. It is my absolute intention to remain focused on the most important part of our business – our clients and our teams.”

He will report to Catherine Warne, head of Creston Health. She said: “Jon is the perfect person to run Pan Advertising – he is experienced, dynamic and very clever.  The news has been greeted very positively by Pan's clients.”

Linscott replaces Claire Dobbs who leaves to join another advertising agency after two years in the role.

Other moves at Pan Advertising include those of Arron O'Hare, who becomes creative director, and Emily Wigginton, who has been promoted to the role of client services director.

27th February 2012

Share

Subscribe to our email news alerts

PMHub

Add my company
11 London

We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...